Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT

Background: Children with juvenile idiopathic arthritis (JIA) are at risk of uveitis. The role of adalimumab (Humira®; AbbVie Inc., Ludwigshafen, Germany) in the management of uveitis in children needs to be determined. Objective: To compare the efficacy, safety and cost-effectiveness of adalimumab...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Athimalaipet V Ramanan, Andrew D Dick, Ashley P Jones, Dyfrig A Hughes, Andrew McKay, Anna Rosala-Hallas, Paula R Williamson, Ben Hardwick, Helen Hickey, Naomi Rainford, Graeme Hickey, Ruwanthi Kolamunnage-Dona, Giovanna Culeddu, Catrin Plumpton, Eifiona Wood, Sandrine Compeyrot-Lacassagne, Patricia Woo, Clive Edelsten, Michael W Beresford
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	NIHR Journals Library 2019-04-01
Edice:	Health Technology Assessment
Témata:	ADALIMUMAB JUVENILE IDIOPATHIC ARTHRITIS RANDOMISED CONTROLLED TRIAL METHOTREXATE OPHTHALMOLOGY PAEDIATRIC RHEUMATOLOGY SAFETY UVEITIS
On-line přístup:	https://doi.org/10.3310/hta23150
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!